Key figures as of March 31, 2017


Cash, cash equivalents and financial assets*


* Including short term investments and non-current financial instruments

Financial debt



166 employees, 3/4 of whom are dedicated to R&D


8 programs in development:

  • 4 programs in clinical trials including one licensed to Bristol-Myers Squibb and one partnered with AstraZeneca
  • 4 proprietary preclinical programs

See FY financial results for 2016